Polycythemia vera (PV) patients experiencing thromboembolic events (TEs) face significantly higher healthcare resource utilization and mortality rates, according to a recent study conducted across numerous US hospitals.
Study Highlights
The retrospective cohort analysis encompassed 3,494 adults with PV and TE discharged from 623 hospitals between January 2017 and June 2020. The average age was 70.7 years, predominantly males and White individuals, with most insured by Medicare. Hospitalization costs averaged $24,403 during the initial TE-related stay, with one-third admitted to intensive care units, incurring higher costs and longer stays.
Healthcare Impact
Readmission rates reached 6.4% within 30 days and 20.0% over two years post-discharge. Mortality during the initial hospitalization was 6.2%, increasing to 10.9% over two years.
– Intensive care unit admissions contributed to elevated hospitalization costs.
– The high readmission rate indicates persistent health challenges post-discharge.
– Mortality rates emphasize the critical nature of managing TEs in PV patients.
The substantial healthcare costs and mortality associated with TEs in PV patients highlight the critical need for preventive measures in managing polycythemia vera. Implementing targeted interventions could not only enhance patient survival but also alleviate the financial strain on healthcare resources.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
